Addition of Curcumin-QingDai correlates with clinical benefit in pediatric ulcerative colitis and inflammatory bowel disease-unclassified

Authors: Sadovi, Francesca; Li, Jiafeng; Gomez, Amanda; Cordova, Jonathan; Prozialeck, Joshua; Strople, Jennifer; Brown, Jeffrey; Runde, Joseph

Source journal: Journal of pediatric gastroenterology and nutrition (2026-11-17)

DOI: 10.1002/jpn3.70683

Abstract

OBJECTIVES: Composite remission remains hard to achieve for patients with inflammatory bowel disease (IBD). Recently, a novel herbal-based combination therapy, Curcumin-QingDai (CurQD), has shown promise in improving rates of clinical remission for adults with ulcerative colitis (UC), however, experience in children is lacking. Here we describe efficacy and safety of CurQD in a pediatric cohort diagnosed with UC/IBD-unclassified (IBD-U). METHODS: We performed a retrospective chart review of children with a diagnosis of UC or IBD-U beginning CurQD. Data collection included demographics, disease extent and severity, medication history, surgical history, biomarkers, endoscopic and histologic reports, and intestinal ultrasound. Clinical disease activity measured by the pediatric ulcerative colitis activity index (PUCAI) was recorded at baseline, Weeks 8-12 and Week 24. RESULTS: A total of 35 patients with UC/IBD-U treated with CurQD met inclusion criteria, 28.6% were female and 62.9% had a diagnosis of UC. The median age at start of intervention was 14.0 years. Twenty-two (62.9%) were bio-experienced. Clinical response and clinical remission rates were 65.5% and 63.6%, respectively, by Week 24. Significant changes in calprotectin, ESR, albumin and hemoglobin were noted pre/post intervention. Side effects to CurQD were uncommon (14.2%) and mild in all cases. CONCLUSIONS: As management options in the pediatric population are limited, adjunctive therapy is often a crucial consideration in achieving clinical response in children with IBD. Our data suggests that the addition of CurQD may offer a safe and effective option for children with UC/IBD-U when a primary agent has not resulted in a durable clinical remission.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.